Jenny C Chang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2821520/publications.pdf

Version: 2024-02-01

128 papers	14,374 citations	36271 51 h-index	30058 103 g-index
132 all docs	132 docs citations	132 times ranked	19749 citing authors

#	Article	IF	Citations
1	Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-6. Npj Breast Cancer, 2022, 8, 30.	2.3	14
2	Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View. Cancers, 2022, 14, 1760.	1.7	20
3	Clinical factors and association with treatment modalities in patients with breast cancer and brain metastases who develop leptomeningeal metastases. Breast Cancer Research and Treatment, 2022, 193, 613-623.	1.1	1
4	A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxanes in the Treatment of Patients With Advanced or Metastatic Anthracycline-refractory Breast Cancer. Clinical Breast Cancer, 2021, 21, 199-204.	1.1	23
5	Analysis of the Implementation of Telehealth Visits for Care of Patients With Cancer in Houston During the COVID-19 Pandemic. JCO Oncology Practice, 2021, 17, e36-e43.	1.4	91
6	Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma. Cell Metabolism, 2021, 33, 78-93.e7.	7.2	57
7	Enhancing Inflammation Targeting Using Tunable Leukocyte-Based Biomimetic Nanoparticles. ACS Nano, 2021, 15, 6326-6339.	7.3	49
8	A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida). Breast Cancer Research and Treatment, 2021, 190, 265-275.	1.1	34
9	Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy. Scientific Reports, 2021, 11, 82.	1.6	16
10	A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer. Science Translational Medicine, 2021, 13, eabj5070.	5.8	48
11	A targetable LIFRâ^'NF-Î¹Bâ^'LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis. Nature Communications, 2021, 12, 7333.	5.8	117
12	A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer. Breast Cancer Research, 2020, 22, 4.	2.2	58
13	Emerging treatment strategies for breast cancer brain metastasis: from translational therapeutics to real-world experience. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093615.	1.4	17
14	A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations. Breast Cancer Research, 2020, 22, 121.	2.2	89
15	Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs. Breast Cancer Research, 2020, 22, 48.	2.2	10
16	Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Research and Treatment, 2020, 181, 623-633.	1.1	6
17	SNX27â€“retromer assembly recycles MT1-MMP to invadopodia and promotes breast cancer metastasis. Journal of Cell Biology, 2020, 219, .	2.3	38
18	Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases. Breast Cancer Research and Treatment, 2019, 178, 251-261.	1.1	15

#	Article	IF	Citations
19	The impact of molecular status on survival outcomes for invasive micropapillary carcinoma of the breast. Breast Journal, 2019, 25, 1171-1176.	0.4	19
20	Prognosis of lymphotropic invasive micropapillary breast carcinoma analyzed by using data from the National Cancer Database. Cancer Communications, 2019, 39, 1-9.	3.7	19
21	A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL) Tj ETQq1 1 0.784314 rgBT /Over		
22	Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/Î²-catenin and TGFÎ² signaling pathways. European Journal of Nutrition, 2019, 58, 3207-3219.	1.8	42
23	Cancer therapeutic targeting using mutantâ€“p53-specific siRNAs. Oncogene, 2019, 38, 3415-3427.	2.6	29
24	HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway. Stem Cell Reports, 2018, 10, 212-227.	2.3	42
25	Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer. Clinical Cancer Research, 2018, 24, 1152-1162.	3.2	62
26	Treatment Outcomes and Prognostic Factors in Male Patients With Stage IV Breast Cancer: AÂPopulation-based Study. Clinical Breast Cancer, 2018, 18, e97-e105.	1.1	8
27	Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Research and Treatment, 2018, 167, 731-740.	1.1	71
28	A Behavior-Modification, Clinical-Grade Mobile Application to Improve Breast Cancer Survivors' Accountability and Health Outcomes. JCO Clinical Cancer Informatics, 2018, 2, 1-11.	1.0	21
29	Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models. Breast Cancer Research, 2018, 20, 108.	2.2	81
30	Activating Transcription Factor 4 Modulates TGFÎ²-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling. Clinical Cancer Research, 2018, 24, 5697-5709.	3.2	42
31	The ERÎ²4 variant induces transformation of the normal breast mammary epithelial cell line MCF-10A; the ERÎ² variants ERÎ²2 and ERÎ²5 increase aggressiveness of TNBC by regulation of hypoxic signaling. Oncotarget, 2018, 9, 12201-12211.	0.8	15
32	A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. Clinical Cancer Research, 2017, 23, 4035-4045.	3.2	104
33	Deep learning analytics for diagnostic support of breast cancer disease management. , 2017, , .		10
34	Role of RPL39 in Metaplastic Breast Cancer. Journal of the National Cancer Institute, 2017, 109, djw292.	3.0	55
35	Molecular characterization of breast cancer CTCs associated with brain metastasis. Nature Communications, 2017, 8, 196.	5.8	148
36	NO and COX2: Dual targeting for aggressive cancers. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 13591-13593.	3.3	34

#	Article	IF	Citations
37	Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Research and Treatment, 2016, 158, 441-454.	1.1	26
38	Breast Cancer Stem Cells. , 2016, , 133-151.		0
39	Cancer stem cells. Medicine (United States), 2016, 95, S20-S25.	0.4	303
40	Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. Cancer Research, 2016, 76, 1942-1953.	0.4	77
41	The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair. Cancer Letters, 2016, 376, 249-258.	3.2	99
42	Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases. Journal of Biological Chemistry, 2016, 291, 23756-23768.	1.6	48
43	Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells. Breast Cancer Research, 2016, 18, 6.	2.2	49
44	The role of combined radiation and immunotherapy in breast cancer treatment. Journal of Radiation Oncology, 2015, 4, 347-354.	0.7	5
45	Epithelial derived CTGF promotes breast tumor progression via inducing EMT and collagen I fibers deposition. Oncotarget, 2015, 6, 25320-25338.	0.8	43
46	Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clinical Cancer Research, 2015, 21, 3995-4003.	3.2	82
47	Therapeutic targeting of casein kinase 1Î´ in breast cancer. Science Translational Medicine, 2015, 7, 318ra202.	5.8	61
48	Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer*. Molecular and Cellular Proteomics, 2015, 14, 1959-1976.	2.5	44
49	Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer. Breast Cancer Research, 2015, 17, 25.	2.2	175
50	Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer. Clinical Cancer Research, 2015, 21, 1688-1698.	3.2	990
51	Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. Cell Research, 2014, 24, 542-559.	5.7	23
52	XBP1 promotes triple-negative breast cancer by controlling the HIF1Î± pathway. Nature, 2014, 508, 103-107.	13.7	663
53	Chloroquine Eliminates Cancer Stem Cells Through Deregulation of Jak2 and DNMT1. Stem Cells, 2014, 32, 2309-2323.	1.4	95
54	Dual HER2 blockade: preclinical and clinical data. Breast Cancer Research, 2014, 16, 419.	2.2	11

#	Article	IF	Citations
55	Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8838-8843.	3.3	99
56	Eniluracil Plus 5-Fluorouracil and Leucovorin: Treatment for Metastatic Breast Cancer Patients in Whom Capecitabine Treatment Rapidly Failed. Clinical Breast Cancer, 2014, 14, 26-30.	1.1	6
57	Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts. Stem Cell Reports, 2014, 2, 78-91.	2.3	854
58	Abstract 3015: Annexin A3 is selectively expressed in MET-like as compared to EMT-like breast cancer stem cells. , 2014, , .		1
59	Abstract 5279: Induced expression of PPM1A in ER-negative breast cancer cells inhibits growth by suppressing cell cycle. , 2014, , .		0
60	Abstract 4024: iNOS inhibition increases survival in triple negative breast cancer by targeting metastasis and epithelial-mesenchymal transition. , 2014, , .		0
61	Studying Cancer Stem Cell Dynamics on PDMS Surfaces for Microfluidics Device Design. Scientific Reports, 2013, 3, 2332.	1.6	59
62	Prognostic Markers for Invasive Micropapillary Carcinoma of the Breast: A Population-Based Analysis. Clinical Breast Cancer, 2013, 13, 133-139.	1.1	38
63	Delivery of gene silencing agents for breast cancer therapy. Breast Cancer Research, 2013, 15, 205.	2.2	27
64	Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Research, 2013, 15, 201.	2.2	80
65	Novel Modeling of Cancer Cell Signaling Pathways Enables Systematic Drug Repositioning for Distinct Breast Cancer Metastases. Cancer Research, 2013, 73, 6149-6163.	0.4	44
66	Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2â€“Overexpressing Breast Cancer: TBCRC 006. Journal of Clinical Oncology, 2013, 31, 1726-1731.	0.8	238
67	Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors. Clinical Cancer Research, 2013, 19, 1512-1524.	3.2	224
68	A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models. Cancer Research, 2013, 73, 4885-4897.	0.4	394
69	Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency. Breast Cancer Research, 2013, 15, R77.	2.2	60
70	Primary systemic therapy in breast cancer. , 2013, , 489-504.		0
71	Abstract A91: Developing novel treatment strategies for triple-negative breast cancer metastasis. , 2013, , .		0
72	Abstract 856: High expression of DUSP4 in ER-negative breast cancer cells suppresses growth and invasion.. , 2013, , .		0

#	Article	IF	Citations
73	Abstract 3909: Assessing the role of tumor vascularity in nanotherapeutics delivery.. , 2013, , .		0
74	Abstract 2586: The natural compound hydroxytyrosol inhibits the Wnt/EMT axis and migration of triple-negative breast cancer cells.. , 2013, , .		1
75	Abstract 2712: Identification of tumor initiating genes RPL39 and MLF2 that mediate lung metastasis through nitric oxide signaling and mesenchymal to epithelial transition.. , 2013, , .		0
76	Abstract 1996: Identification of four subgroups of Triple Negative Breast Cancer (TNBC) by genomic profiling.. , 2013, , .		0
77	Abstract 237: Chloroquine inhibits cancer stem cells in triple negative breast cancer via regulation of DNA methylation.. , 2013, , .		0
78	A Novel Method of Transcriptional Response Analysis to Facilitate Drug Repositioning for Cancer Therapy. Cancer Research, 2012, 72, 33-44.	0.4	85
79	Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Research, 2012, 14, 202.	2.2	204
80	Microfluidics separation reveals the stem-cellâ€“like deformability of tumor-initiating cells. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 18707-18712.	3.3	186
81	Microenvironmental Regulation of Epithelialâ€“Mesenchymal Transitions in Cancer. Cancer Research, 2012, 72, 4883-4889.	0.4	265
82	A gene transcription signature of obesity in breast cancer. Breast Cancer Research and Treatment, 2012, 132, 993-1000.	1.1	48
83	The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models. Breast Cancer Research and Treatment, 2012, 131, 425-436.	1.1	38
84	Selective Small Molecule Stat3 Inhibitor Reduces Breast Cancer Tumor-Initiating Cells and Improves Recurrence Free Survival in a Human-Xenograft Model. PLoS ONE, 2012, 7, e30207.	1.1	56
85	Abstract 2853: Discovery of phosphatases that regulate growth and tumorigenicity of ER-negative breast cancers. , 2012, , .		0
86	Abstract 4862: Autocrine secreted IL-6 and IL-8 play critical and non-redundant roles in basal-like breast cancer cell transformation and growthin vitroandin vivo. , 2012, , .		0
87	Abstract 2857: Induced expression of DUSP4 and PPM1A in ER-negative breast cancer cells suppresses proliferation and invasion. , 2012, , .		0
88	Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2â€“Overexpressing Locally Advanced Breast Cancers. Journal of Clinical Oncology, 2011, 29, 166-173.	0.8	235
89	Reply to M. Russillo et al. Journal of Clinical Oncology, 2011, 29, 2835-2835.	0.8	0
90	Abstract 4370: Network-based signatures for drug repositioning and combination for the breast tumor initiating cells. , 2011, , .		0

#	Article	IF	Citations
91	Abstract 1664: Maternal embryonic leucine aipper kinase (MELK) is a critical regulator of proliferation and is independently prognostic in estrogen receptor-negative breast cancer. , 2011, , .		0
92	Abstract LB-110: Bioinformatic discovery of repositioned drugs to target breast tumor initiating cells. , 2011, , .		0
93	Abstract 231: Upregulation of HER3 (ErbB3) levels and function counteracts the antitumor effect of HER2 and PI3K inhibitors. , 2011, , .		0
94	Abstract LB-106: Expression of stem cell biomarkers in benign breast tissue from patients with triple negative breast cancer. , 2011, , .		0
95	Self-blame, Self-forgiveness, and Spirituality in Breast Cancer Survivors in a Public Sector Setting. Journal of Cancer Education, 2010, 25, 343-348.	0.6	35
96	Epithelial-Mesenchymal Transition (EMT) in Tumor-Initiating Cells and Its Clinical Implications in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2010, 15, 253-260.	1.0	229
97	Decreased TGFÎ² signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Research and Treatment, 2010, 119, 305-314.	1.1	56
98	Thermal Enhancement with Optically Activated Gold Nanoshells Sensitizes Breast Cancer Stem Cells to Radiation Therapy. Science Translational Medicine, 2010, 2, 55ra79.	5.8	167
99	Enhanced Mammary Progesterone Receptor-A Isoform Activity in the Promotion of Mammary Tumor Progression by Dietary Soy in Rats. Nutrition and Cancer, 2010, 62, 774-782.	0.9	8
100	Abstract 16: Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. , 2010, , .		1
101	Pharmacogenetics of Breast Cancer: Toward the Individualization of Therapy. Cancer Investigation, 2009, 27, 699-703.	0.6	3
102	Identification of Novel Kinase Targets for the Treatment of Estrogen Receptorâ€“Negative Breast Cancer. Clinical Cancer Research, 2009, 15, 6327-6340.	3.2	89
103	Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13820-13825.	3.3	1,257
104	Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Research and Treatment, 2008, 108, 233-240.	1.1	123
105	Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy. Journal of the National Cancer Institute, 2008, 100, 672-679.	3.0	1,632
106	HER2 Inhibition: From Discovery to Clinical Practice: Fig. 1.. Clinical Cancer Research, 2007, 13, 1-3.	3.2	38
107	Regulators of Mitotic Arrest and Ceramide Metabolism Are Determinants of Sensitivity to Paclitaxel and Other Chemotherapeutic Drugs. Cancer Cell, 2007, 11, 498-512.	7.7	351
108	Attribution of Blame, Self-forgiving Attitude and Psychological Adjustment in Women with Breast Cancer. Journal of Behavioral Medicine, 2007, 30, 351-357.	1.1	58

#	Article	IF	Citations
109	Optimism, social support and psychosocial functioning among women with breast cancer. Psycho-Oncology, 2006, 15, 595-603.	1.0	156
110	Self-Forgiveness, Spirituality, and Psychological Adjustment in Women with Breast Cancer. Journal of Behavioral Medicine, 2006, 29, 29-36.	1.1	97
111	Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance. Breast Cancer Research and Treatment, 2006, 95, 229-233.	1.1	88
112	Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Research and Treatment, 2005, 94, 279-284.	1.1	30
113	Patterns of Resistance and Incomplete Response to Docetaxel by Gene Expression Profiling in Breast Cancer Patients. Journal of Clinical Oncology, 2005, 23, 1169-1177.	0.8	189
114	Utility of microarrays in the management of breast cancer patients. Drug Discovery Today: Therapeutic Strategies, 2005, 2, 307-311.	0.5	0
115	The promise of microarrays in the management and treatment of breast cancer. Breast Cancer Research, 2005, 7, 100-4.	2.2	25
116	Endocrine prevention of breast cancer. , 2005, , 30-34.		0
117	Survival of patients with metastatic breast carcinoma. Cancer, 2003, 97, 545-553.	2.0	237
118	Neoadjuvant Trastuzumab and Docetaxel in Patients With Breast Cancer: Preliminary Results. Clinical Breast Cancer, 2003, 4, 348-353.	1.1	92
119	Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet, The, 2003, 362, 362-369.	6.3	804
120	Ductal lavage and the clinical management of women at high risk for breast carcinoma. Cancer, 2002, 94, 292-298.	2.0	51
121	Reversible and Irreversible Cardiac Dysfunction Associated with Trastuzumab in Breast Cancer. Breast Cancer Research and Treatment, 2002, 74, 131-134.	1.1	11
122	Pharmacology, biology and clinical use of triphenylethylenes. , 2002, , 33-44.		0
123	Clinical management of women with genomic BRCA1 and BRCA2 mutations*. Breast Cancer Research and Treatment, 2001, 69, 101-113.	1.1	25
124	Benign and Malignant Breast Masses and Axillary Nodes: Evaluation with Echo-enhanced Color Power Doppler US. Radiology, 2001, 220, 795-802.	3.6	83
125	Patients with Breast Cancer: Differences in Color Doppler Flow and Gray-Scale US Features of Benign and Malignant Axillary Lymph Nodes. Radiology, 2000, 215, 568-573.	3.6	161
126	Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet, The, 1998, 352, 98-101.	6.3	678

#	Article	IF	Citations
127	Non-surgical aspects of ovarian cancer. Lancet, The, 1994, 343, 335-340.	6.3	17
128	SERMs and Breast Cancer Prevention. , 0, , 267-278.		0